ETF monthly wrap-up

Christine St Anne  |  30/10/2012Text size  Decrease  Increase  |  

Christine St Anne: In this month's exchange traded fund or ETF wrap up. I'm joined by Alex Prineas, who talks to us about how the products have performed and the new product from UBS.

Alex welcome.

Alex Prineas: Thanks, Christine.

St Anne: Alex, so, what were the best performing ETFs in the month of September?

Prineas: The best performing ETFs were mostly commodity related. So, we saw an announcement of policy from the US Federal Reserve. It's been dubbed QE-Infinity. It's basically a commitment to continue the policy of quantitative easing indefinitely.

So, that has all sorts of repercussions some of which have do with possibly debasing the US dollar and so precious metal ETFs were popular in September. So, we saw things like ETFS Physical Silver was up more than 12 per cent and we also saw strong runs from the ETFS Physical Platinum and BetaShares gold bullion.

There were also some industrial and energy products that also did well. So, ETFS Natural Gas and ETFS Industrial Commodities ETF were both up more than 10 per cent each. The only non-commodity related ETF that performed strongly although it was in the top 10 over the month was iShares MSCI Hong Kong product, but we know that the Hong Kong dollar is pegged to the US dollar. So, when you get an announcement quantitative easing, you can't say a liquidity injection into Hong Kong, so that may have been related.

St Anne: The not so good performers?

Prineas: Well, funnily enough, the worst performing ETFs were also commodity related products and I think that highlights in the short run, the commodity complex doesn't necessarily move in unison, but the worst performing products were more agricultural or oil related. So, we saw ETFS Agriculture and BetaShares Crude Oil both down around 5 per cent. Oil prices were limited during the month by an oil production pledge from Saudi Arabia and then it wasn't surprising to see some weakness in agricultural commodity prices. They had a very strong run in the previous few months on the back of the U.S. drought.

I guess commodity prices can be volatile and they can also be un-correlated to other asset classes they can be affected by things like crop yields, the weather, political decisions. So we often see commodity related ETFs at the top or bottom of performance tables in the short run and this month they dominated both the top and the bottom of the tables.

St Anne: Alex, UBS has recently launched a new ETF product. Can you give us an insight into this product and how it differs from the existing ETFs out there in the market?

Prineas: Yeah, the UBS product is an interesting one and it's based on buy ratings from UBS's fundamental equity research team. They have some quality filters overlaid, so you end up with a 40 stock portfolio. But ultimately I guess you could say it is a rules based ETF, but those rules are based on an underlying group of equity investors looking for attractive stocks.

So, UBS can't market it as an active ETF, because the regulation in Australia doesn't allow that. But essentially it is an ETF with an active stock selection component to it or a listed fund, I guess you could call it. The pricing also suggests that that's where it's pitched with a fee of 0.7 per cent. Looks quite expensive if you compare it to passive or index based ETFs. But if you compare it to an actively managed fund, say your average Australian shares, unit trust or super fund, the pricing looks more competitive. So, UBS's product is an interesting development. It's an example of the lines being blurred between ETFs and actively managed unit trusts or funds.

St Anne: Alex, thanks so much for your insights today.

Prineas: Thanks Christine.

Video Archive...

Xero underlines returning popularity of technology stocks
19/07/2016  The success of accounting software company Xero is part of a broader resurgence of technology companies, contrasting with the shifting fortunes of Australia's resources sector.
Zurich Investments Global Thematic
18/07/2016  Morningstar's Kathryn Young explains what sets Zurich Investments Global Thematic apart from rival global equities strategies.
Gold Managers: Platinum International Fund
15/07/2016  Morningstar's Kathryn Young explains what makes Platinum International a standout strategy and the rationale behind the fund's Gold rating.
Gold Managers: Magellan Global Fund
15/07/2016  Morningstar's Tim Wong explains why the Magellan Global Equities was upgraded to Gold and why there is more to the strategy than Hamish Douglass.
Is this graph to blame for Brexit?
13/07/2016  Britain's vote to leave the European Union seems to tie in with a feeling across the Western world--a rebellion against globalisation and those in power.
Global equities versus Aussie equities
11/07/2016  While global equities may be attractive on a relative valuation basis, it's important not to blindly follow a benchmark, Morningstar Investment Management's Brad Bugg says.
Forecast 2016-17: Exercise caution
08/07/2016  Morningstar's Peter Warnes shares his thoughts on the past year, his expectations for the year ahead, as well as a few important recommendations.
Breaking from the pack in asset allocation
04/07/2016  Morningstar Investment Management's Andrew Lill explains the benefits of long-term, valuation-driven asset allocation, while also elaborating on his team's definition of "risk".
A permanent state of distorted reality
30/06/2016  Hamish Douglass, chief executive officer, Magellan Financial Group, explains why he believes we are at an odd point in history with the Brexit vote, ineffectual central bank policies and volatile currencies.
How should investors react to Brexit result?
28/06/2016  Dan Kemp of Morningstar UK says investors need to keep cool, calm heads amid political and financial uncertainty as to what happens next, following the Brexit vote.
Behavioural finance and how it hits your bottom line
28/06/2016  Understanding how your thought patterns drive investment decisions could amount to hundreds of thousands of dollars over your lifetime, explains behavioural finance expert Simon Russell.
Bogle on Brexit and other threats to global markets
21/06/2016  We have more borrowing, more leverage, more government debt relative to GDP than we have ever had with no attempt to get it down, says Vanguard founder Jack Bogle.
Are we heading for another recession?
21/06/2016  After an incredible rally across developed market equities and global bonds, the good times may be over. Should investors be selling up for cash and gold?
Buy the world in a couple of trades
20/06/2016  As the popularity of ETFs continues to skyrocket in Australia, Morningstar asks Jon Howie, head of iShares Australia how ongoing market volatility affects investors in this space.
2 asset classes presenting value
16/06/2016  While most asset classes may be a bit on the expensive side, Schroders' Simon Stevenson believes pockets of reasonable value can still be found.
Combining active and passive investment management
08/06/2016  Active investing versus index investing isn’t necessarily a prescriptive “one or the other” approach, explains Stephen van Eyk.
What does China’s credit situation really mean for global investors?
08/06/2016  The head of Stephen van Eyk Consulting outlines why he believes China's high rate of credit relative to GDP introduces considerable risk for global markets and investors.
Big banks on attractive dividend yields
02/06/2016  Morningstar's David Ellis points out where he sees value in the financials sector, including among the big banks and the major insurers, while also discussing a few of the headwinds facing these companies.
Investment opportunities: Oil breaks through $50 a barrel
01/06/2016  After falling to below $30 a barrel earlier this year, oil has broken through the $50 mark. Stephen Message from UK-based asset manager Old Mutual examines what this means for stocks.
Platinum bullish on US pharma and Chinese tech stocks
25/05/2016  Platinum managing director Kerr Neilson gives insights into the asset manager's approach and areas of investment focus, with a particularly keen outlook on US pharmaceuticals and Chinese technology stocks.